The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides.
AuthorsRenehan, Andrew G
O'Dwyer, Sarah T
Shalet, Stephen M
AffiliationDepartment of Surgery, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. email@example.com
MetadataShow full item record
AbstractBACKGROUND: Oral estrogen alone (EA) decreases concentrations of total IGF-I while increasing IGFBP-1, but data on other IGF-related peptides are inconsistent and/or sparse. Combined oral estrogen and progestin (EP) may have differential effects on IGF-related peptides dependent on its progestin-associated androgenic activity. The aim of this study was to clarify these relationships, as circulating IGF-related peptides are potential surrogates of predisposition to common chronic diseases. DESIGN: Using an open-labelled cross-sectional design within a bowel cancer screening trial (aged 55-64 years), we determined total IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in fasted serum from 210 healthy women and free IGF-I (by ultrafiltration), insulin, IGFBP-1 and IGFBP-1:IGF-I binary complex in a selected subset of 92 women. Unadjusted and adjusted (using generalized linear models) means were compared. RESULTS: Among EA users, mean concentrations for total IGF-I (adjusted P=0.004) and free IGF-I (P<0.001) were reduced, whereas mean concentrations of IGFBP-1 (P=0.001) and binary complex (P=0.01) were increased compared with non-users. Taken as a whole group, EP use was not associated with differences in concentrations of IGF-related peptides, but on sub-group analyses, mean concentrations associated with the use of progestins with reduced androgenic activity reflected the use of EA. By contrast, mean IGFBP-2 concentrations were significantly reduced among both EA (P=0.008) and EP (P=0.002) users, irrespective of androgenic activity. Neither EA nor EP influenced mean concentrations of IGF-II, insulin and IGFBP-3. CONCLUSIONS: The uses of oral sex steroid replacements are associated with significant changes in several IGF-related analytes in a preparation-specific manner, suggesting different regulatory mechanisms. However, the directions of these changes do not fit simple correlative models of predisposition to common diseases.
CitationThe effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. 2007, 17 (3):210-9 Growth Horm. IGF Res.
JournalGrowth Hormone & IGF Research
- Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
- Authors: Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, Gibson MJ
- Issue date: 2005 Mar
- Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.
- Authors: Helle SI, Omsjø IH, Hughes SC, Botta L, Hüls G, Holly JM, Lønning PE
- Issue date: 1996 Dec
- The insulin-like growth factor-I system and hormone replacement therapy.
- Authors: Cardim HJ, Lopes CM, Giannella-Neto D, da Fonseca AM, Pinotti JA
- Issue date: 2001 Feb
- The effect of laparoscopy on the IGF system in patients diagnosed with acute cholecystitis.
- Authors: Baricević I, Jones DR, Malenković V, Nedić O
- Issue date: 2006 Sep
- Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.
- Authors: Heald A, Selby PL, White A, Gibson JM
- Issue date: 2000 Sep